Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

2438 - Ototoxicity in locally advanced head and neck cancer (LAHNC) patients (pts) treated with induction chemotherapy (IC) followed by cisplatin-based chemoradiotherapy (CRT)


09 Oct 2016


Poster display


Chantal Driessen


Annals of Oncology (2016) 27 (6): 328-350. 10.1093/annonc/mdw376


C. Driessen1, A. Snik2, J. Leijendeckers2, J.P. de Boer3, H. Gelderblom4, C. van Opstal1, W. van der Graaf1, J. Kaanders5, C. van Herpen1

Author affiliations

  • 1 Department Of Medical Oncology/452, Radboud University Medical Centre Nijmegen, 6500 HB - Nijmegen/NL
  • 2 Ear, Nose And Thraot Department, Radboud University Medical Centre Nijmegen, 6500 HB - Nijmegen/NL
  • 3 Medical Oncology, Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), 1006 BE - Amsterdam/NL
  • 4 Clinical Oncology, Leiden University Medical Center (LUMC), 2300 - Leiden/NL
  • 5 Radiation Oncology, Radboud University Medical Centre Nijmegen, 6500 HB - Nijmegen/NL


Abstract 2438


The CONDOR study, a randomized phase II study, investigated feasibility of docetaxel/cisplatin/5-fluorouracil (TPF) followed by conventional radiotherapy with cisplatin 100 mg/m2 on days 1, 22, 43 (cis100 + RT) versus accelerated radiotherapy with cisplatin weekly 40 mg/m2(cis40 + ART) in LAHNC pts. The effect of the two regimens on ototoxicity was investigated.


Audiometry was carried out at baseline, during and after TPF before start of CRT, and 1, 4, 8 and 12 months after end of treatment. Air-conduction thresholds were determined in octave steps from 1 kHz until 8 kHz. Where 1 to 4 kHz is relevant for speech. Based on baseline thresholds we divided the pts in two groups; pts with baseline thresholds  50 dB.


62 pts started with TPF; 56 pts were randomized to cis100 + RT (n = 27) or cis40 + ART (n = 29). Compliance to audiometry was low, mostly due to poor physical condition. Pts included in this analysis were 12 in cis100 + RT and 11 in cis40 + ART. Mean cumulative cisplatin dose was 498 mg/m2 (SD 66.1) for cis100 + RT and 490 mg/m2 (SD 55.8) for cis40 + ART (p = 0.75). Hearing deterioration over time was gradually for cis40 + ART and abrupt for cis100 + RT; with a wide spread in both groups. Mostly, the abrupt hearing deterioration occurred during CRT. Hearing loss was most prominent at 8 kHz and almost absent at 2 kHz. We used the Wilcoxon test for our hypothesis that pts treated with cis100 + RT suffer more hearing loss than pts treated with cis40 + ART; showing a difference for 8 kHz (z = 2.07; p = 0.03) and 4 kHz (z = 1.98, p = 0.04). Analysis for hearing deterioration in the subgroup of baseline hearing  50 dB mean deterioration was less, approximately 10 dB. In 15 pts we could compare data from 12 versus 4 months after end of treatment. These showed no clinically relevant at 8 kHz.

Frequency Cis100 + RT Cis40 + ART
8 kHz 41 dB 20 dB
4 kHz 30 dB 12 dB
2 kHz 7 dB 3 dB


After TPF CRT with cis40 + ART is less ototoxic than CRT with cis100 + RT.

Clinical trial identification


Legal entity responsible for the study

Carla van Herpen


Sanovi Aventis Netherlands Dutch Cancer Society


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings